Search for content, post, videos

NeuroVive in new research agreement

magnus-hansson-neurovive

NeuroVive Pharmaceutical has signed a preclinical collaboration agreement with the Children’s Hospital of Philadelphia (CHOP) and Marni J. Falk, M.D., a US opinion leader in the mitochondrial medicine field.

Dr. Falk’s research team at CHOP will evaluate compounds from NeuroVive’s research program, NVP015, in certain experimental disease models. The research team will study energy metabolism and disease development in models of mitochondrial complex I dysfunction.

Marni J. Falk. is an attending physician and director of the Mitochondrial Disease Clinical Center at CHOP, US, which is a large center for children and adults with mitochondrial disorders and a leading mitochondrial disease research center. Dr. Falk’s experience spans all the way from early experimental research through to clinical development and covers the whole drug development process.CHOP is one of the world’s largest children’s hospitals and has consistently been ranked as one of the best hospitals for children in the US.

“We feel fortunate to be able to initiate this collaboration with a well-recognized institution like CHOP and Dr. Marni Falk, a well-esteemed leader in the mitochondrial disease field. This is an important step in further advancing and strengthening our NVP015 program, as well as in the development of novel treatment opportunities for people with mitochondrial medicine disorders,” commented NeuroVive’s CMO Magnus Hansson.

 

Leave a Reply

Your email address will not be published. Required fields are marked *

20 − 2 =